Eli Lilly and Incyte announced that baricitinib showed high rates of hair regrowth in adolescents with severe alopecia areata (AA) in the Phase 3 BRAVE-AA-PEDS study. At week 36, 42.4% of patients receiving baricitinib 4 mg achieved at least 80% scalp hair coverage, compared to 4.5% on placebo. The treatment also led to significant eyebrow and eyelash regrowth.

The study enrolled 257 patients aged 12 to under 18, with most experiencing near-total hair loss at baseline. Patients receiving baricitinib 4 mg also showed greater improvement in hair regrowth compared to those on a lower dose (2 mg) or placebo. The results suggest adolescents may respond faster to treatment than adults.

The safety profile was consistent with prior studies, with common adverse events including acne, influenza, and upper respiratory infections. No major cardiovascular events, malignancies, or deaths were reported.

Lilly plans to present further data at upcoming scientific meetings and discuss findings with regulators. Baricitinib is already FDA-approved for adults with severe AA and is marketed as Olumiant.